Checkpoint Therapeutics (NASDAQ:CKPT) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a report issued on Monday morning,Benzinga reports. D. Boral Capital currently has a $4.80 price objective on the stock, down from their previous price objective of $9.00.

Several other equities research analysts have also commented on CKPT. Lake Street Capital boosted their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a report on Monday, December 16th.

Checkpoint Therapeutics Trading Up 61.1 %

CKPT stock opened at $3.98 on Monday. The company’s 50-day moving average price is $3.10 and its 200 day moving average price is $3.08. Checkpoint Therapeutics has a 52 week low of $1.38 and a 52 week high of $4.50. The company has a market cap of $194.36 million, a P/E ratio of -2.16 and a beta of 1.41.

Insiders Place Their Bets

In other news, CFO William Garrett Gray sold 74,110 shares of the company’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total value of $271,983.70. Following the sale, the chief financial officer now directly owns 1,458,644 shares in the company, valued at $5,353,223.48. This represents a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James F. Oliviero III sold 10,331 shares of Checkpoint Therapeutics stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $3.15, for a total value of $32,542.65. Following the sale, the chief executive officer now owns 3,775,019 shares of the company’s stock, valued at approximately $11,891,309.85. This represents a 0.27 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 582,336 shares of company stock worth $2,156,801. Insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CKPT. Geode Capital Management LLC grew its holdings in shares of Checkpoint Therapeutics by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 445,111 shares of the company’s stock worth $1,425,000 after buying an additional 17,460 shares in the last quarter. 683 Capital Management LLC acquired a new stake in Checkpoint Therapeutics during the fourth quarter worth approximately $522,000. HB Wealth Management LLC grew its stake in Checkpoint Therapeutics by 96.9% in the 4th quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock worth $513,000 after acquiring an additional 75,560 shares during the period. PVG Asset Management Corp raised its holdings in Checkpoint Therapeutics by 9.2% in the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after acquiring an additional 12,676 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of Checkpoint Therapeutics by 160.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after purchasing an additional 80,000 shares during the period. 22.00% of the stock is currently owned by hedge funds and other institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.